A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma

RecruitingOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

August 20, 2022

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions

Hepatocellular Carcinoma

Trial Locations (1)

RECRUITING

Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou

All Listed Sponsors

collaborator

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

lead

Meng Chao Hepatobiliary Hospital of Fujian Medical University

OTHER